Below are the financial statements of Kobayashi Pharmaceutical, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of JPY | 2024 2024-01-01 - 2024-12-31 | 2023 2023-01-01 - 2023-12-31 |
|---|---|---|
| Net sales | 165,600a | 173,455a |
| Cost of sales | -77,997a | -77,079a |
| Gross profit | 87,603a | 96,375a |
| Selling, general and administrative expenses | — | — |
| Sales promotion expenses | -3,435a | -3,690a |
| Freight and storage | -5,294a | -4,704a |
| Advertising expenses | -8,140a | -19,348a |
| Salaries, allowances and bonuses | -16,289a | -14,849a |
| Retirement benefit expenses | -765a | -887a |
| Taxes and dues | -753a | -930a |
| Depreciation | -3,433a | -2,076a |
| Amortization of goodwill | -1,407a | -1,128a |
| Rent | -1,558a | -1,521a |
| Fees paid | -5,160a | -5,419a |
| Research and development expenses | -9,109a | -9,004a |
| Other | -7,391a | -7,035a |
| Selling, general and administrative expenses total | -62,742a | -70,595a |
| Operating income | 24,860a | 25,780a |
| Non-operating income | — | — |
| Interest income | 207a | 214a |
| Dividend income | 608a | 548a |
| Real estate rental income | 300a | 295a |
| Foreign exchange gain | 330a | 40a |
| Compensation income | 347a | 451a |
| Other | 683a | 636a |
| Non-operating income total | 2,477a | 2,187a |
| Non-operating expenses | — | — |
| Interest expense | -28a | -29a |
| Real estate rental cost | -106a | -105a |
| Provision for doubtful accounts | -151a | -154a |
| Other | -189a | -347a |
| Non-operating expenses total | -476a | -637a |
| Ordinary income | 26,861a | 27,330a |
| Extraordinary income | — | — |
| Gain on sale of fixed assets | 21a | 11a |
| Gain on sale of investment securities | 635a | 436a |
| Other | 4a | 14a |
| Extraordinary income total | 662a | 461a |
| Extraordinary losses | — | — |
| Loss on disposal of fixed assets | -72a | -70a |
| Product recall-related losses | -12,524a | 0a |
| Other | -1,012a | -161a |
| Extraordinary losses total | -13,609a | -232a |
| Income before income taxes | 13,914a | 27,559a |
| Current income taxes | -5,240a | -8,297a |
| Deferred income taxes | -1,398a | -1,076a |
| Income taxes total | -3,842a | -7,221a |
| Net income | 10,071a | 20,338a |
| Net income attributable to noncontrolling interests | 4a | 0a |
| Net income attributable to owners of parent | 10,067a | 20,338a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.